Patterns and predictors of COVID-19 vaccine uptake among United States active duty Service members, 2020-2022: Implications for future pandemics
Sercy, E.; Stewart, L.; Craig-Kuhn, M. C.; Stern, C.; Graham, B.; Michel, A.; Parmelee, E.; Pollett, S.; Burgess, T.; Tribble, D. R.
Show abstract
IntroductionVaccine mandates have been used to minimize the duty days lost and deaths attributable to infectious disease among active duty Service members (ADSMs). In response to the global COVID-19 pandemic, in August 2021, the United States Department of Defense issued a COVID-19 vaccine mandate for all ADSMs. This study aimed to investigate COVID-19 vaccine uptake among the ADSM population, as well as factors associated with timing of COVID-19 vaccine receipt. MethodsThis study included ADSMs on active duty between 1/1/2020-6/30/2022. Univariate analyses investigated associations between demographic factors (age, sex, race, ethnicity, branch of service, rank, state of residence) and COVID-19 diagnosis with the following outcomes: 1) time to primary series initiation in relation to the DoD vaccine mandate, 2) time between doses of the two-dose primary series, and 3) time between booster eligibility and receipt ResultsA total of 1,799,466 ADSMs were included, with 90% receiving [≥]1 COVID-19 vaccine dose during the study period and 77% initiating the primary series prior to the mandate. Over 80% of ADSMs received a complete primary series, with 96% of those adhering to the recommended regimen. History of COVID-19 diagnosis was associated with later receipt of all doses. ConclusionsCOVID-19 vaccine uptake was high among all ADSMs, with the majority initiating the primary series before the mandate. The high vaccine uptake among ADSMs shown here may be used as a guide to both military and civilian pandemic policy and outreach efforts related to enhanced vaccine uptake.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis 96%
- 2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims 96%
- Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting 95%
Similar papers in this journal
- Assessment of COVID-19 vaccine acceptance among healthcare workers in Los Angeles 94%
- Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial 93%
- Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization and death: a target trial emulation in the omicron (B.1.1.529) variant era 92%
Similar papers in this journal
Similar papers in this journal
- Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis 95%
- Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers 94%
- Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine 93%
Similar papers in this journal
- Self-Reported SARS-CoV-2 Vaccination is Consistent with Electronic Health Record Data among the COVID-19 Community Research Partnership 94%
- Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine 94%
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.